Boston-based startup InnoTech Precision Medicine is collaborating with the Massachusetts Institute of Technology to develop a biosensor platform that multiplexes antigen and nucleic acid biomarkers to test for SARS-CoV-2 and other medical conditions.
The developers are leveraging the strengths of antigen and nucleic acid testing by “multiplexing up to eight biosensors for selective detection of their corresponding protein and nucleic acid targets,” said Roya Khosravi-Far, InnoTech’s CEO and cofounder.
Roya Khosravi-Far is a 2021 MassNextGen recipient. The MLSC program is a five year, more than $2 million commitment to ensure greater gender parity in the next generation of life science entrepreneurs.
